Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 105

1.

Factors in the emergence of serious human infections associated with highly pathogenic strains of shiga toxin-producing Escherichia coli.

Karmali MA.

Int J Med Microbiol. 2018 Dec;308(8):1067-1072. doi: 10.1016/j.ijmm.2018.08.005. Epub 2018 Aug 19. Review.

PMID:
30146439
2.

Emerging Public Health Challenges of Shiga Toxin-Producing Escherichia coli Related to Changes in the Pathogen, the Population, and the Environment.

Karmali MA.

Clin Infect Dis. 2017 Feb 1;64(3):371-376. doi: 10.1093/cid/ciw708. Epub 2016 Oct 21. Review.

PMID:
27986670
3.

Dietary patterns and ethnicity are associated with distinct plasma proteomic groups.

García-Bailo B, Brenner DR, Nielsen D, Lee HJ, Domanski D, Kuzyk M, Borchers CH, Badawi A, Karmali MA, El-Sohemy A.

Am J Clin Nutr. 2012 Feb;95(2):352-61. doi: 10.3945/ajcn.111.022657. Epub 2011 Dec 28.

PMID:
22205312
4.

Rapid genoserotyping tool for classification of Salmonella serovars.

Franklin K, Lingohr EJ, Yoshida C, Anjum M, Bodrossy L, Clark CG, Kropinski AM, Karmali MA.

J Clin Microbiol. 2011 Aug;49(8):2954-65. doi: 10.1128/JCM.02347-10. Epub 2011 Jun 22.

5.

Serological response of Shiga toxin-producing Escherichia coli type III secreted proteins in sera from vaccinated rabbits, naturally infected cattle, and humans.

Asper DJ, Karmali MA, Townsend H, Rogan D, Potter AA.

Clin Vaccine Immunol. 2011 Jul;18(7):1052-7. doi: 10.1128/CVI.00068-11. Epub 2011 May 18.

6.

Genome sequence of adherent-invasive Escherichia coli and comparative genomic analysis with other E. coli pathotypes.

Nash JH, Villegas A, Kropinski AM, Aguilar-Valenzuela R, Konczy P, Mascarenhas M, Ziebell K, Torres AG, Karmali MA, Coombes BK.

BMC Genomics. 2010 Nov 25;11:667. doi: 10.1186/1471-2164-11-667.

7.

In silico genomic analyses reveal three distinct lineages of Escherichia coli O157:H7, one of which is associated with hyper-virulence.

Laing CR, Buchanan C, Taboada EN, Zhang Y, Karmali MA, Thomas JE, Gannon VP.

BMC Genomics. 2009 Jun 29;10:287. doi: 10.1186/1471-2164-10-287.

8.

Verocytotoxin-producing Escherichia coli (VTEC).

Karmali MA, Gannon V, Sargeant JM.

Vet Microbiol. 2010 Jan 27;140(3-4):360-70. doi: 10.1016/j.vetmic.2009.04.011. Epub 2009 Apr 10. Review.

PMID:
19410388
9.

Enterohemorrhagic Escherichia coli O157:H7 gene expression profiling in response to growth in the presence of host epithelia.

Jandu N, Ho NK, Donato KA, Karmali MA, Mascarenhas M, Duffy SP, Tailor C, Sherman PM.

PLoS One. 2009;4(3):e4889. doi: 10.1371/journal.pone.0004889. Epub 2009 Mar 18.

10.

Host and pathogen determinants of verocytotoxin-producing Escherichia coli-associated hemolytic uremic syndrome.

Karmali MA.

Kidney Int Suppl. 2009 Feb;(112):S4-7. doi: 10.1038/ki.2008.608. Review.

11.

Genomic O island 122, locus for enterocyte effacement, and the evolution of virulent verocytotoxin-producing Escherichia coli.

Konczy P, Ziebell K, Mascarenhas M, Choi A, Michaud C, Kropinski AM, Whittam TS, Wickham M, Finlay B, Karmali MA.

J Bacteriol. 2008 Sep;190(17):5832-40. doi: 10.1128/JB.00480-08. Epub 2008 Jun 27.

12.

The continuing evolution of a bacterial pathogen.

Kaper JB, Karmali MA.

Proc Natl Acad Sci U S A. 2008 Mar 25;105(12):4535-6. doi: 10.1073/pnas.0801435105. Epub 2008 Mar 19. No abstract available.

13.

Molecular analysis as an aid to assess the public health risk of non-O157 Shiga toxin-producing Escherichia coli strains.

Coombes BK, Wickham ME, Mascarenhas M, Gruenheid S, Finlay BB, Karmali MA.

Appl Environ Microbiol. 2008 Apr;74(7):2153-60. doi: 10.1128/AEM.02566-07. Epub 2008 Feb 1.

14.

Applicability of phylogenetic methods for characterizing the public health significance of verocytotoxin-producing Escherichia coli strains.

Ziebell K, Konczy P, Yong I, Frost S, Mascarenhas M, Kropinski AM, Whittam TS, Read SC, Karmali MA.

Appl Environ Microbiol. 2008 Mar;74(5):1671-5. doi: 10.1128/AEM.01619-07. Epub 2007 Dec 28.

15.

Isolation and genetic characterization of a coinfection of non-O157 Shiga toxin-producing Escherichia coli.

Gilmour MW, Tabor H, Wang G, Clark CG, Tracz DM, Olson AB, Mascarenhas M, Karmali MA, Mailman T, Ng LK.

J Clin Microbiol. 2007 Nov;45(11):3771-3. Epub 2007 Sep 5.

16.

Citrobacter rodentium virulence in mice associates with bacterial load and the type III effector NleE.

Wickham ME, Lupp C, Vázquez A, Mascarenhas M, Coburn B, Coombes BK, Karmali MA, Puente JL, Deng W, Finlay BB.

Microbes Infect. 2007 Mar;9(3):400-7. Epub 2007 Jan 13.

PMID:
17317262
17.

Multiple seropathotypes of verotoxin-producing Escherichia coli (VTEC) disrupt interferon-gamma-induced tyrosine phosphorylation of signal transducer and activator of transcription (Stat)-1.

Jandu N, Shen S, Wickham ME, Prajapati R, Finlay BB, Karmali MA, Sherman PM.

Microb Pathog. 2007 Feb-Mar;42(2-3):62-71. Epub 2006 Dec 15.

PMID:
17174521
18.

Bacterial genetic determinants of non-O157 STEC outbreaks and hemolytic-uremic syndrome after infection.

Wickham ME, Lupp C, Mascarenhas M, Vazquez A, Coombes BK, Brown NF, Coburn BA, Deng W, Puente JL, Karmali MA, Finlay BB.

J Infect Dis. 2006 Sep 15;194(6):819-27. Epub 2006 Aug 11.

PMID:
16941350
19.
20.
21.

SepZ/EspZ is secreted and translocated into HeLa cells by the enteropathogenic Escherichia coli type III secretion system.

Kanack KJ, Crawford JA, Tatsuno I, Karmali MA, Kaper JB.

Infect Immun. 2005 Jul;73(7):4327-37.

22.

The association between idiopathic hemolytic uremic syndrome and infection by verotoxin-producing Escherichia coli. 1985.

Karmali MA, Petric M, Lim C, Fleming PC, Arbus GS, Lior H.

J Infect Dis. 2004 Feb 1;189(3):556-63. No abstract available.

PMID:
14982069
23.

Evidence for a hybrid genomic island in verocytotoxin-producing Escherichia coli CL3 (serotype O113:H21) containing segments of EDL933 (serotype O157:H7) O islands 122 and 48.

Shen S, Mascarenhas M, Rahn K, Kaper JB, Karmali MA.

Infect Immun. 2004 Mar;72(3):1496-503. Erratum in: Infect Immun. 2004 Jul;72(7):4330. Karmal MA [corrected to Karmali MA].

24.

Infection by Shiga toxin-producing Escherichia coli: an overview.

Karmali MA.

Mol Biotechnol. 2004 Feb;26(2):117-22. Review.

PMID:
14764937
25.
26.

Age-specific frequencies of antibodies to Escherichia coli verocytotoxins (Shiga toxins) 1 and 2 among urban and rural populations in southern Ontario.

Karmali MA, Mascarenhas M, Petric M, Dutil L, Rahn K, Ludwig K, Arbus GS, Michel P, Sherman PM, Wilson J, Johnson R, Kaper JB.

J Infect Dis. 2003 Dec 1;188(11):1724-9. Epub 2003 Nov 14.

PMID:
14639544
27.

Association of genomic O island 122 of Escherichia coli EDL 933 with verocytotoxin-producing Escherichia coli seropathotypes that are linked to epidemic and/or serious disease.

Karmali MA, Mascarenhas M, Shen S, Ziebell K, Johnson S, Reid-Smith R, Isaac-Renton J, Clark C, Rahn K, Kaper JB.

J Clin Microbiol. 2003 Nov;41(11):4930-40.

28.

The medical significance of Shiga toxin-producing Escherichia coli infections. An overview.

Karmali MA.

Methods Mol Med. 2003;73:1-7. Review. No abstract available.

PMID:
12375423
29.
30.

Shiga toxin-producing Escherichia coli infection and antibodies against Stx2 and Stx1 in household contacts of children with enteropathic hemolytic-uremic syndrome.

Ludwig K, Sarkim V, Bitzan M, Karmali MA, Bobrowski C, Ruder H, Laufs R, Sobottka I, Petric M, Karch H, Müller-Wiefel DE.

J Clin Microbiol. 2002 May;40(5):1773-82.

31.

Antibodies to intimin and Escherichia coli secreted proteins A and B in patients with enterohemorrhagic Escherichia coli infections.

Karpman D, Békássy ZD, Sjögren AC, Dubois MS, Karmali MA, Mascarenhas M, Jarvis KG, Gansheroff LJ, O'Brien AD, Arbus GS, Kaper JB.

Pediatr Nephrol. 2002 Mar;17(3):201-11.

PMID:
11956862
32.

Cross-protection against challenge by intravenous Escherichia coli verocytotoxin 1 (VT1) in rabbits immunized with VT2 toxoid.

Ludwig K, Karmali MA, Smith CR, Petric M.

Can J Microbiol. 2002 Jan;48(1):99-103.

PMID:
11888169
33.

Antibody response to Shiga toxins Stx2 and Stx1 in children with enteropathic hemolytic-uremic syndrome.

Ludwig K, Karmali MA, Sarkim V, Bobrowski C, Petric M, Karch H, Müller-Wiefel DE; Arbeitsgemeinschaft für Pädiatrische Nephrologie.

J Clin Microbiol. 2001 Jun;39(6):2272-9.

34.

Escherichia coli Shiga toxins induce apoptosis in epithelial cells that is regulated by the Bcl-2 family.

Jones NL, Islur A, Haq R, Mascarenhas M, Karmali MA, Perdue MH, Zanke BW, Sherman PM.

Am J Physiol Gastrointest Liver Physiol. 2000 May;278(5):G811-9.

35.

The nature of immunity to the Escherichia coli Shiga toxins (verocytotoxins) and options for toxoid immunization.

Karmali MA.

Jpn J Med Sci Biol. 1998;51 Suppl:S26-35. Review. No abstract available.

PMID:
10211434
37.

Isolation and characterization of sorbitol-fermenting Shiga toxin (Verocytotoxin)-producing Escherichia coli O157:H- strains in the Czech Republic.

Bielaszewska M, Schmidt H, Karmali MA, Khakhria R, Janda J, Bláhová K, Karch H.

J Clin Microbiol. 1998 Jul;36(7):2135-7.

38.

Risk factors for infection with verocytotoxigenic Escherichia coli in cattle on Ontario dairy farms.

Wilson JB, Renwick SA, Clarke RC, Rahn K, Alves D, Johnson RP, Ellis AG, McEwen SA, Karmali MA, Lior H, Spika J.

Prev Vet Med. 1998 Feb 27;34(2-3):227-36.

PMID:
9604270
39.

Inhibition of Helicobacter pylori and Helicobacter mustelae binding to lipid receptors by bovine colostrum.

Bitzan MM, Gold BD, Philpott DJ, Huesca M, Sherman PM, Karch H, Lissner R, Lingwood CA, Karmali MA.

J Infect Dis. 1998 Apr;177(4):955-61.

PMID:
9534968
40.

Human Escherichia coli O157:H7 infection associated with the consumption of unpasteurized goat's milk.

Bielaszewska M, Janda J, Bláhová K, Minaríková H, Jíková E, Karmali MA, Laubová J, Sikulová J, Preston MA, Khakhria R, Karch H, Klazarová H, Nyc O.

Epidemiol Infect. 1997 Dec;119(3):299-305.

41.

Translocation of verotoxin-1 across T84 monolayers: mechanism of bacterial toxin penetration of epithelium.

Philpott DJ, Ackerley CA, Kiliaan AJ, Karmali MA, Perdue MH, Sherman PM.

Am J Physiol. 1997 Dec;273(6):G1349-58. doi: 10.1152/ajpgi.1997.273.6.G1349.

PMID:
9435561
42.

Verocytotoxin inhibits mitogenesis and protein synthesis in purified human glomerular mesangial cells without affecting cell viability: evidence for two distinct mechanisms.

Van Setten PA, van Hinsbergh VW, Van den Heuvel LP, van der Velden TJ, van de Kar NC, Krebbers RJ, Karmali MA, Monnens LA.

J Am Soc Nephrol. 1997 Dec;8(12):1877-88.

43.

Canadian Perspectives on Verocytotoxin-Producing Escherichia coli Infection .

Wilson JB, Johnson RP, Clarke RC, Rahn K, Renwick SA, Alves D, Karmali MA, Michel P, Orrbine E, Spika JS.

J Food Prot. 1997 Nov;60(11):1451-1453. doi: 10.4315/0362-028X-60.11.1451.

PMID:
31207770
45.

Toxicity and immunogenicity of a verotoxin 1 mutant with reduced globotriaosylceramide receptor binding in rabbits.

Bast DJ, Brunton JL, Karmali MA, Richardson SE.

Infect Immun. 1997 Jun;65(6):2019-28.

46.
47.

Heterogeneity in phenotypic and genotypic characteristics among strains of Hafnia alvei.

Ismaili A, Bourke B, de Azavedo JC, Ratnam S, Karmali MA, Sherman PM.

J Clin Microbiol. 1996 Dec;34(12):2973-9.

48.

Vero cytotoxigenic Escherichia coli infection in dairy farm families.

Wilson JB, Clarke RC, Renwick SA, Rahn K, Johnson RP, Karmali MA, Lior H, Alves D, Gyles CL, Sandhu KS, McEwen SA, Spika JS.

J Infect Dis. 1996 Nov;174(5):1021-7.

PMID:
8896504
49.

Growing Concerns and Recent Outbreaks Involving Non-O157:H7 Serotypes of Verotoxigenic Escherichia coli.

Johnson RP, Clarke RC, Wilson JB, Read SC, Rahn K, Renwick SA, Sandhu KA, Alves D, Karmali MA, Lior H, McEwen SA, Spika JS, Gyles CL.

J Food Prot. 1996 Oct;59(10):1112-1122. doi: 10.4315/0362-028X-59.10.1112.

PMID:
31195470
50.

Neutralizing antibodies to Escherichia coli Vero cytotoxin 1 and antibodies to O157 lipopolysaccharide in healthy farm family members and urban residents.

Reymond D, Johnson RP, Karmali MA, Petric M, Winkler M, Johnson S, Rahn K, Renwick S, Wilson J, Clarke RC, Spika J.

J Clin Microbiol. 1996 Sep;34(9):2053-7.

Supplemental Content

Loading ...
Support Center